Evidence map›Paper›PMID 41945592›Full record

ArticlePloS one2026

Expanding the toolkit of LacI/GalR chimeras.

Carter J Gray, Pierce T O'Neil, Kristen M Schwingen, Carrie Hillebrand, Liskin Swint-Kruse

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carter J GrayMedical Professions Academy, Olathe North High School, Olathe, Kansas, United States.ORCID https://orcid.org/0009-0009-8226-5101
Pierce T O'NeilDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas, United States.
Kristen M SchwingenDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas, United States.
Carrie HillebrandDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas, United States.
Liskin Swint-KruseDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas, United States.ORCID https://orcid.org/0000-0002-5925-9741

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When creating synthetic transcription circuits, multi-input regulation is desirable. However, the size and complexity of prokaryotic circuits are constrained by the number of transcription factors that can simultaneously bind a promoter region. This limitation has been circumvented by leveraging the conserved architecture of LacI/GalR transcription repressors: The DNA binding domain of one repressor can be fused to paralogous ligand binding domains that bind different allosteric ligands; function can be optimized by mutating domain interfaces. When such chimeras were used in prior studies to co-regulate transcription, their set of allosteric ligands conveyed Boolean "AND", "NOT", and "NOR" logic from a single DNA operator. Here, we report construction and characterization of additional chimeras that can be used to expand the LacI/GalR toolkit. For both novel and previously reported chimeras, we assessed (and in most cases ruled out) cross reactivity among their ligands. As such, we propose that three of the novel chimeras, along with a previously uncharacterized fourth chimera, could be co-expressed in engineered systems to expand the options available for Boolean "AND" logic. Gratuitous inducers were identified for another prior chimera that would allow "OR" logic using a single transcription factor. Surprisingly, another novel chimera was anti-induced by the ligand that induces its parent protein. This allosteric switch illustrates what may be a general feature of the LacI/GalR proteins: they appear poised to switch between induction and anti-induction via changes in ligands or amino acid mutations. Practically speaking, this anti-induced chimera could be co-expressed with a previous anti-induced chimera to perform "NOR" logic.

Indexed as

ChimeraEscherichia coli ProteinsLac RepressorsRepressor ProteinsTranscription, GeneticAllosteric RegulationLigandsProkaryotic Initiation FactorsEscherichia coli ProteinsGalactose repressor proteinsLacI protein, E coliLac RepressorsLigandsProkaryotic Initiation FactorsRepressor Proteins

Identifiers

PMID41945592
PMCPMC13056197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.